JP7588859B2 - グラム陰性細菌の感染、汚染、及びファウリングを予防及び治療するための新規ピリミジン誘導体 - Google Patents

グラム陰性細菌の感染、汚染、及びファウリングを予防及び治療するための新規ピリミジン誘導体 Download PDF

Info

Publication number
JP7588859B2
JP7588859B2 JP2021561852A JP2021561852A JP7588859B2 JP 7588859 B2 JP7588859 B2 JP 7588859B2 JP 2021561852 A JP2021561852 A JP 2021561852A JP 2021561852 A JP2021561852 A JP 2021561852A JP 7588859 B2 JP7588859 B2 JP 7588859B2
Authority
JP
Japan
Prior art keywords
sch
nhch
difluorophenyl
cyclopropyl
nch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021561852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529052A (ja
JP2022529052A5 (cg-RX-API-DMAC7.html
Inventor
ランセロッティ,パトリツィオ
ウリ,セシル
ピロット,ベルナール
ムスメチ,ルシア
ジャック,ニコラ
ゴファン,エリク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Liège
Original Assignee
University of Liège
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Liège filed Critical University of Liège
Publication of JP2022529052A publication Critical patent/JP2022529052A/ja
Publication of JP2022529052A5 publication Critical patent/JP2022529052A5/ja
Application granted granted Critical
Publication of JP7588859B2 publication Critical patent/JP7588859B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/713—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with four or more nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
JP2021561852A 2019-04-18 2020-04-17 グラム陰性細菌の感染、汚染、及びファウリングを予防及び治療するための新規ピリミジン誘導体 Active JP7588859B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19170003 2019-04-18
EP19170003.8 2019-04-18
EP19188639.9 2019-07-26
EP19188639 2019-07-26
PCT/EP2020/060819 WO2020212553A1 (en) 2019-04-18 2020-04-17 New pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling

Publications (3)

Publication Number Publication Date
JP2022529052A JP2022529052A (ja) 2022-06-16
JP2022529052A5 JP2022529052A5 (cg-RX-API-DMAC7.html) 2023-04-24
JP7588859B2 true JP7588859B2 (ja) 2024-11-25

Family

ID=70480222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021561852A Active JP7588859B2 (ja) 2019-04-18 2020-04-17 グラム陰性細菌の感染、汚染、及びファウリングを予防及び治療するための新規ピリミジン誘導体

Country Status (10)

Country Link
US (1) US12318388B2 (cg-RX-API-DMAC7.html)
EP (1) EP3955929B1 (cg-RX-API-DMAC7.html)
JP (1) JP7588859B2 (cg-RX-API-DMAC7.html)
KR (1) KR102857084B1 (cg-RX-API-DMAC7.html)
CN (1) CN113329753B (cg-RX-API-DMAC7.html)
AU (1) AU2020258017B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012834A2 (cg-RX-API-DMAC7.html)
DK (1) DK3955929T3 (cg-RX-API-DMAC7.html)
ES (1) ES2981773T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020212553A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3527571A1 (en) * 2018-02-14 2019-08-21 Université de Liège Pyrimidine derivatives for prevention and treatment of bacterial infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018046174A1 (en) 2016-09-09 2018-03-15 Universite De Liege New use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
JP2022541371A (ja) 2019-07-25 2022-09-26 ユニベルシテ・ド・リエージュ トリアゾロ[4,5-d]ピリミジン誘導体の新規な使用法
JP7316672B2 (ja) 2018-02-14 2023-07-28 ユニベルシテ・ド・リエージュ 細菌感染を予防及び処置するためのピリミジン誘導体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4928399A (en) * 1998-07-27 2000-02-21 M & M Laboratory Co., Ltd. Ion complex, coating material, and coating method
WO2004021979A2 (en) * 2002-09-06 2004-03-18 Smithkline Beecham Corporation PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
DE102005060690B4 (de) * 2005-12-15 2008-09-25 Capsulution Nanoscience Ag Salze von Clopidogrel mit Polyanionen und ihre Verwendung zur Herstellung pharmazeutischer Formulierungen
WO2009034386A1 (en) 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
EP2236158A1 (en) * 2009-03-30 2010-10-06 Pharnext New therapeutic approaches for treating neuroinflammatory conditions
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018046174A1 (en) 2016-09-09 2018-03-15 Universite De Liege New use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
JP7075667B2 (ja) 2016-09-09 2022-05-26 ユニベルシテ・ド・リエージュ 細菌感染の予防および治療のためのトリアゾロ(4,5-d)ピリミジン誘導体の新規な使用
JP7316672B2 (ja) 2018-02-14 2023-07-28 ユニベルシテ・ド・リエージュ 細菌感染を予防及び処置するためのピリミジン誘導体
JP2022541371A (ja) 2019-07-25 2022-09-26 ユニベルシテ・ド・リエージュ トリアゾロ[4,5-d]ピリミジン誘導体の新規な使用法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Molecules,2019年01月,24,249, page 1-15

Also Published As

Publication number Publication date
KR102857084B1 (ko) 2025-09-10
BR112021012834A2 (pt) 2021-09-28
DK3955929T3 (da) 2024-08-05
US20210290625A1 (en) 2021-09-23
WO2020212553A1 (en) 2020-10-22
AU2020258017A1 (en) 2021-07-01
KR20220003556A (ko) 2022-01-10
ES2981773T3 (es) 2024-10-10
JP2022529052A (ja) 2022-06-16
CN113329753A (zh) 2021-08-31
AU2020258017B2 (en) 2025-05-29
EP3955929B1 (en) 2024-05-15
US12318388B2 (en) 2025-06-03
CN113329753B (zh) 2024-08-13
CA3128304A1 (en) 2020-10-22
EP3955929A1 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
KR102678805B1 (ko) 박테리아 감염의 예방 및 치료를 위한 피리미딘 유도체
JP5657642B2 (ja) リバースターン類似体の新規な化合物およびその製造方法と用途
JP6140083B2 (ja) 三環式ジャイレース阻害薬
US20170217964A1 (en) Aminotetrahydropyran derivative used as dipeptidyl peptidaseiv inhibitor
JP2019506365A (ja) アミノ金ホスフィン錯体に基づいた抗菌化合物
JP2019502667A (ja) 抗菌化合物
US12318388B2 (en) Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling
JP2008515979A (ja) フラザノ‘3,4−ビピラジン(bipyrazine)及び抗腫瘍剤としてのその使用
EP2643301B1 (fr) Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses
CA3128304C (en) Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling
WO2019042442A1 (zh) 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物
CA3090945C (en) Pyrimidine derivatives for prevention and treatment of bacterial infections
BR112020009290B1 (pt) Derivados de pirimidina, seu método de preparação e seu uso, composição farmacêutica, e método ex vivo para matar ou impedir o crescimento bacteriano na formação de biofilme
HUP0204476A2 (en) Therapeutically useful new salts of cck inhibitors, process for the preparation thereof and pharmaceutical compositions containing them
JP7354245B2 (ja) ピロロピリミジン骨格を有する新規なカーボネート化合物又はその薬学的に許容可能な塩
US20230310481A1 (en) Bi- and monocyclic nucleoside analogs for treatment of hepatitis e

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241022

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241106

R150 Certificate of patent or registration of utility model

Ref document number: 7588859

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150